Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Novel immunotherapy 5F9 plus rituximab well tolerated with rapid and durable responses in R/R DLBCL and indolent lymphoma

EHA 2019

13 - 16 Jun 2019

Published: 15 Jun 2019

Views: 1373

Rating:

Save

Dr Mark Roschewski - National Cancer Institute, Bethesda, USA

Dr Mark Roschewski presents results at the 2019 European Hematology Association (EHA) Annual Meeting from a study looking at the novel immunotherapy 5F9 plus rituximab which blocks CD47, a key macrophage/cancer checkpoint.

The 100 patients studied with the treatment were well tolerated and showed good durability.

Related Videos

Advancements in minimal residual disease detection in myeloma

Dory Abelman, PhD Candidate - University of Toronto, Ontario, Canada

Advancements in minimal residual disease detection in myeloma ( Dory Abelman, PhD Candidate - University of Toronto, Ontario, Canada )

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM

Dr Elias Mai - Heidelberg University, Heidelberg, Germany

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM ( Dr Elias Mai - Heidelberg University, Heidelberg, Germany )

Guiding transplant decisions in multiple myeloma with MRD

Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA

Guiding transplant decisions in multiple myeloma with MRD ( Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA )

ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer

Prof Karim Fizazi, Dr Anders Bjartell, Dr Niven Mehra and Prof Eleni Efstathiou

ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer ( Prof Karim Fizazi, Dr Anders Bjartell, Dr Niven Mehra and Prof Eleni Efstathiou )

ASCO 2024: Lung cancer highlights

Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas Girard and Dr Anna Minchom

ASCO 2024: Lung cancer highlights ( Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas Girard and Dr Anna Minchom )

Treatment of multiple myeloma in Turkey

Dr Güldane Cengiz Seval - Ankara University, Ankara, Turkey

Treatment of multiple myeloma in Turkey ( Dr Güldane Cengiz Seval - Ankara University, Ankara, Turkey )

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )

Multiple myeloma in a resource constrained setting

Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda

Multiple myeloma in a resource constrained setting ( Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda )

Vitamin D in patients with low tumour-burden indolent non-Hodgkin lymphoma treated with rituximab therapy

Dr Jonathan Friedberg - University of Rochester, Rochester, USA

Vitamin D in patients with low tumour-burden indolent non-Hodgkin lymphoma treated with rituximab therapy ( Dr Jonathan Friedberg - University of Rochester, Rochester, USA )

More from ecancer